Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;17(2):88-91.
doi: 10.17925/EE.2021.17.2.88. Epub 2021 Nov 10.

Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes

John Doupis  1 , Neoklis Baris  1 , Konstantinos Avramidis  1
Affiliations
Review

Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes

John Doupis et al. touchREV Endocrinol. 2021 Nov.

Abstract

Imeglimin is a novel molecule currently under development for the treatment of type 2 diabetes mellitus, and is the first agent of the 'glimin' class of glucose-lowering medication. It has a unique mechanism of action that targets the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis and increased β-cell apoptosis. To date, imeglimin has been evaluated in many preclinical and clinical trials and has shown to have notable antihyperglycaemic effects, such as statistically significant reductions in glycated haemoglobin, fasting plasma glucose and other glycaemic parameters. The encouraging tolerability profile, combined with its efficacy, could make it suitable as a monotherapy or in combination with other classes of antidiabetic agents, hopefully in the near future.

Keywords: Type 2 diabetes mellitus; clinical trials; imeglimin; mechanism of action.

PubMed Disclaimer

Conflict of interest statement

Disclosures: John Doupis, Neoklis Baris and Konstantinos Avramidis have no financial or non-financial relationships or activities to declare in relation to this article.

References

    1. Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A potential new multi-target drug for type 2 diabetes. Drugs R D. 2015;15:227–32. - PMC - PubMed
    1. Yendapally R, Sikazwe D, Kim SS. et al. A review of phenformin, metformin, and imeglimin. Drug Dev Res. 2020;81:390–401. - PubMed
    1. Yaribeygi H, Maleki M, Sathyapalan T. et al. Molecular mechanisms by which imeglimin improves glucose homeostasis. J Diabetes Res. 2020;2020:8768954. - PMC - PubMed
    1. Hallakou-Bozec S, Vial G, Kergoat M. et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23:664–73. - PMC - PubMed
    1. Clémence C, Fouqueray P, Sébastien B. In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans. Drug Metab Dispos. 2020;48:1330–46. - PubMed

LinkOut - more resources